These changes in receptor expression represent a dynamic mechanism that modulates the cellular response to IL-1β in RA (19) The critical role of this axis is underscored by the therapeutic use of IL-1-blocking agents, such as the recombinant IL-1Ra Anakinra, which can reduce inflammation (20). Here, IL1A is linked to rheumatoid arthritis.